Novo Nordisk Slashes Insulin Prices by Up to 70 Percent

Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024. 

"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."

Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month. 

The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses. 

Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent. 

More In Business

Musk loses crown as world’s richest to software giant Larry Ellison

Oracle co-founder Larry Ellison wrested the title of the world’s richest man from longtime holder Elon Musk early Wednesday as stock in his software giant rocketed more than a third in a stunning few minutes of trading. That is according to wealth tracker Bloomberg. A college dropout, the 81-year-old Ellison is now worth $393 billion, Bloomberg says, several billion more than Musk, who had been the world’s richest for four years. The switch in the ranking came after a blockbuster earnings report from Oracle. Forbes still has Musk as the richest, however, valuing his private businesses much higher.

The Man Studios Listen To: Kevin Goetz on Testing 3,000+ Films at Screen Engine

Kevin Goetz, CEO of Screen Engine, shares how testing 3,000+ films—including Barbie—helps studios shape stories audiences love.

Scaling Prefab with AI: Dextall CEO Aurimas Sabulis Tackles Housing Crisis

Aurimas Sabulis, CEO of Dextall, unveils how AI‑driven prefabricated façades slash design time by 80%, labor by 87%, and accelerate affordable housing delivery.

Home Prices Continue to Rise Despite Declining Sales

U.S. home sales slowed to their weakest pace in nearly 14 years, with rising mortgage rates and affordability concerns affecting market activity.

Jobs Report Underwhelms as Job Growth Stalls

Mark Hamrick of Bankrate helps make sense of the jobs report despite inflation but warns that uncertainty around tariffs could disrupt growth.

Star Trek plans Lego sets for the franchise’s 60th anniversary

Not many franchises have fueled society’s timeless fascination with the boundless possibilities of a utopian future like “Star Trek.”

Robinhood joins new band of companies calling the S&P 500 their home

Online broker Robinhood Markets will join the S&P 500 index Online broker Robinhood Markets will join the S&P 500 index as its stock rides higher on a cryptocurrency wave.

How you too can become a Hollywood insider at a test screening

Anyone can sign up to attend a test screening before a movie is completed.

Big Business This Week: Why does the Fed’s independence matter?

Trump wants interest rates to plummet to make borrowing cheaper and boost growth. Fed chair Jerome Powell and his allies say not so fast, they need to bala

LSD shows promise for reducing anxiety in drugmaker’s midstage study

A midstage study of the psychedelic drug LSD showed positive results for easing symptoms in people with generalized anxiety disorder.

Load More